Abstract
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Current Cancer Therapy Reviews
Title: Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Abstract: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462503
DOI https://dx.doi.org/10.2174/157339412799462503 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Current Topics in Medicinal Chemistry Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Modifications in the upper or Velbenamine Part of the Vinca Alkaloids have Major Implications for Tubulin Interacting Activities
Current Pharmaceutical Design Cytotoxic and Antitumoral Activity of N-(9H-purin-6-yl) Benzamide Derivatives and Related Water-soluble Prodrugs
Current Molecular Pharmacology Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Pediatric Health Effects of Chronic Exposure to Extremely Low Frequency Electromagnetic Fields
Current Pediatric Reviews STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Interaction of Human Brain Acetylcholinesterase with Cyclophosphamide: A Molecular Modeling and Docking Study
CNS & Neurological Disorders - Drug Targets Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Kavalactone Pharmacophores for Major Cellular Drug Targets
Mini-Reviews in Medicinal Chemistry Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry